Chemistry:NIBR2130
NIBR2130, also known as 6-(phenylcarbamoyl)-6-nor-LSD, is a small-molecule chemokine CXCR3 receptor antagonist which has been used in scientific research.[1][2][3] It is a lysergamide and is a derivative of the psychedelic drug lysergic acid diethylamide (LSD).[1]
In contrast to LSD, NIBR2130 shows profoundly reduced affinities for monoamine receptors (IC50 = 750–>10,000 nM).[1] Instead, it was surprisingly found to act as a selective and highly potent chemokine CXCR3 receptor antagonist, with an affinity (IC50) of 54 nM and an inhibitory potency (IC50) of 18 to 74 nM.[1] Unlike NIBR2130, LSD itself is completely inactive at the chemokine CXCR3 receptor.[1] NIBR2130 can fully block the chemokine CXCR3 receptor in rodents in vivo.[3]
Various analogues of NIBR2130 have also been studied and described, with some of them substantially more potent as chemokine CXCR3 receptor antagonists and some of them acting as highly potent histamine H3 receptor antagonists with potential applications in treatment of narcolepsy.[1][4][5]
NIBR2130 was first described in the scientific literature by 2008.[3][1][2]
See also
- Substituted lysergamide
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead". Bioorganic & Medicinal Chemistry Letters 19 (21): 6185–6188. November 2009. doi:10.1016/j.bmcl.2009.09.002. PMID 19783143.
- ↑ 2.0 2.1 "Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model". Clinical and Experimental Immunology 165 (3): 318–328. September 2011. doi:10.1111/j.1365-2249.2011.04426.x. PMID 21649647.
- ↑ 3.0 3.1 3.2 "The chemokine receptor Cxcr3 is not essential for acute cardiac allograft rejection in mice and rats". American Journal of Transplantation 8 (8): 1604–1613. August 2008. doi:10.1111/j.1600-6143.2008.02309.x. PMID 18557719.
- ↑ "Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood". Bioorganic & Medicinal Chemistry Letters 21 (16): 4745–4749. August 2011. doi:10.1016/j.bmcl.2011.06.070. PMID 21764306.
- ↑ "Ergoline-derived inverse agonists of the human h3 receptor for the treatment of narcolepsy". ChemMedChem 9 (8): 1683–1696. August 2014. doi:10.1002/cmdc.201402055. PMID 24850792.
 |  |
